X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Pyrimethamine is indicated for the treatment of toxoplasmosis when used conjointly with a sulfonamide, since synergism exists with this combination. This product is the only ABrated generic version Daraprim® (pyrimethamine) Tablets approved by the USFDA.
Lead Product(s): Pyrimethamine
Therapeutic Area: Infections and Infectious Diseases Product Name: Pyrimethamine-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2020
Details:
Through the acquisition, Tilda Sciences gain two medicines, Daraprim (pyrimethamine), approved for treatment of toxoplasmosis and Vecamyl (mecamylamine HCI), approved for management of hypertension, from Vyera Pharmaceuticals.
Lead Product(s): Pyrimethamine
Therapeutic Area: Infections and Infectious Diseases Product Name: Daraprim
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Tilde Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 07, 2023
Details:
Through the agreement, Phoenixus gains access to Daraprim, a prescription medication that contains pyrimethamine for the treatment of toxoplasmosis and Vecamyl (mecamylamine HCI), indicated for the management of moderately severe to severe essential hypertension.
Lead Product(s): Pyrimethamine
Therapeutic Area: Infections and Infectious Diseases Product Name: Daraprim
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Phoenixus
Deal Size: $0.6 million Upfront Cash: Undisclosed
Deal Type: Agreement August 01, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
